LAG3 and adrenal cortex carcinoma: While most PRs occurred in patients with tumor types known to respond to anti-PD-1 antibodies, antitumor activity was observed in several tumor types where previous effectiveness of immunotherapy has not been established in a consistent way, including adrenocortical carcinoma and PD-L1-negative TNBC (online supplemental figure A1,2).29 In addition, the duration of response has exceeded 4 years in some patients, suggesting that long-term combination therapy is tolerable (figure 4B) and potentially augmented by LAG-3 blockade.